February 12, 2026 10:55 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
BJP MP files notice to cancel Rahul Gandhi's Lok Sabha membership, seeks life-long ban | Arrested in the morning, out by evening: Tycoon’s son walks free in Lamborghini crash case | ‘Why should you denigrate a section of society?’: Supreme Court pulls up ‘Ghooskhor Pandat’ makers | Bangladesh poll manifestos mirror India’s welfare schemes as BNP, Jamaat bet big on women, freebies | Drama ends: Pakistan makes U-turn on India boycott, to play T20 World Cup clash as per schedule | ‘Won’t allow any impediment in SIR’: Supreme Court pulls up Mamata govt over delay in sharing officers’ details | India-US trade deal: ‘Negotiations always two-way’, says Amul MD amid farmers’ concerns | Khamenei breaks 37-year-old ritual for first time amid escalating Iran-US tensions | India must push for energy independence amid global uncertainty: Vedanta chairman Anil Agarwal | Kanpur horror: Lamborghini driven by businessman’s son rams vehicles, injures six
UK | COVID booster vaccine

UK approves COVID-19 booster vaccine for people over 40 years

| @indiablooms | Nov 16, 2021, at 01:32 am

London/UNI/Sputnik: The United Kingdom’s Joint Committee on Vaccination and Immunisation (JCVI) on Monday announced that people over 40 years old living in the country will now be eligible to receive a booster COVID-19 vaccine six months after having their second dose, as a new study showed that boosters give over 90 percent protection in adults over 50.

“JCVI has previously advised booster vaccination for all adults aged 50 years and over and those in a Covid-19 at-risk group. The offer has now been broadened to include those aged 40 to 49 years,” the committee said in a statement.

The booster vaccines to be offered to this new age group are Pfizer-BioNTech and Moderna, the same mRNA-type vaccine that has been used since September in people over 50 and at higher risk from the coronavirus SARS-CoV-2.

So far, more than 12,6 million people in the UK have had the third dose.

According to a study released on Monday by the UK Health Security Agency, two weeks after receiving a booster dose, protection against symptomatic infection in adults aged 50 years and over was 93.1 percent in those who first had AstraZeneca as their primary vaccine and 94.0 percent for Pfizer-BioNTech.

The JCVI also advised that all 16- to 17-year-olds who are not in an at-risk group should be offered a second dose of the Pfizer vaccine 12 weeks or more following the first vaccine dose.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.